Income From Provision Of Diagnostics Service was the largest of Prenetics Global Ltd’s 2 reported lines in fiscal 2025, at $1.29M — 75% of $1.72M.
| Products and services [axis] | FY 2022 | FY 2023 | FY 2025 |
|---|---|---|---|
| Prevention & Diagnostics - Discontinued Operation | $787.79M | — | — |
| Prevention - Genetic Testing | $39.49M | — | — |
| Prevention & Diagnostics - Covid-19 Related And Emea Operations | — | $36.14M | — |
| Act Genomics | — | $8.43M | — |
| Diagnostics - Sale Of Precision Oncology Services | — | $4.49M | — |
| Income From Provision Of Diagnostics Service | — | — | $1.29M |
| Sales Of Laboratory Testing Kits | — | — | $430.73K |
| Total | $827.28M | $49.06M | $1.72M |
In fiscal 2025, which ended December 31, 2025, the 2 revenue lines Prenetics Global Ltd reported in this breakdown added up to $1.72M. The revenue lines reported changed from fiscal 2023, so the total is not directly comparable with the $49.06M reported that year. Income From Provision Of Diagnostics Service was the largest revenue line, at $1.29M or 75.0% of the total, followed by Sales Of Laboratory Testing Kits ($430.73K, 25.0%).
Income From Provision Of Diagnostics Service (fiscal 2025) and Sales Of Laboratory Testing Kits (fiscal 2025) were first reported as separate revenue lines during this period. The table also keeps 5 revenue lines that Prenetics Global Ltd no longer reports, so earlier years can still be read on their original basis; use "Show 5 discontinued" beneath the table to see them. This breakdown covers 3 fiscal years between 2022 and 2025, as reported in Prenetics Global Ltd's annual filings.
Taiwan was the largest of Prenetics Global Ltd’s 4 reported lines in fiscal 2023, at $27.98M — 43% of $65.23M.
| Geography | FY 2020 | FY 2021 | FY 2022 | FY 2023 |
|---|---|---|---|---|
| Hong Kong | $106.23M | $37.60M | $632.80M | $26.89M |
| United Kingdom | $89.30M | — | $194.48M | $6.81M |
| Taiwan | — | — | — | $27.98M |
| Rest Of The World | — | — | — | $3.55M |
| Total | $195.54M | $37.60M | $827.28M | $65.23M |
In fiscal 2023, which ended December 31, 2023, the 4 regions Prenetics Global Ltd reported in this breakdown added up to $65.23M. The regions reported changed from fiscal 2022, so the total is not directly comparable with the $827.28M reported that year. Taiwan was the largest region, at $27.98M or 42.9% of the total, followed by Hong Kong ($26.89M, 41.2%) and United Kingdom ($6.81M, 10.4%). Together, the two largest regions made up 84.1% of this total.
Compared with fiscal 2022, every sizeable region reported in both years shrank. Hong Kong held up best, down 95.8% to $26.89M, while United Kingdom fell the most, down 96.5% to $6.81M. Because regions were added or dropped between the two years, part of this reflects how Prenetics Global Ltd regrouped its reporting.
Taiwan (fiscal 2023) and Rest Of The World (fiscal 2023) were first reported as separate regions during this period. This breakdown covers every fiscal year from 2020 to 2023, as reported in Prenetics Global Ltd's annual filings.
Diagnostics was the largest of Prenetics Global Ltd’s 2 reported lines in fiscal 2023, at $46.76M — 72% of $65.23M.
| Segment | FY 2020 | FY 2021 | FY 2023 |
|---|---|---|---|
| Diagnostics | $152.74M | — | $46.76M |
| Prevention | $42.79M | $37.60M | $18.47M |
| Total | $195.54M | $37.60M | $65.23M |
In fiscal 2023, which ended December 31, 2023, the 2 segments Prenetics Global Ltd reported in this breakdown added up to $65.23M. The segments reported changed from fiscal 2021, so the total is not directly comparable with the $37.60M reported that year. Diagnostics was the largest segment, at $46.76M or 71.7% of the total, followed by Prevention ($18.47M, 28.3%).
Over fiscal 2020 to 2023, revenue across these segments went from $195.54M to $65.23M, a compound annual decline of 30.6%. Diagnostics' share of the total fell from 78.1% to 71.7% over the same years.
This breakdown covers 3 fiscal years between 2020 and 2023, as reported in Prenetics Global Ltd's annual filings.
Prenetics Global Ltd (PRE) breaks its revenue down by revenue line, region and segment. In fiscal 2025, its largest revenue line was Income From Provision Of Diagnostics Service, with $1.29M or 75.0% of the total, followed by Sales Of Laboratory Testing Kits at $430.73K (25.0%).
Income From Provision Of Diagnostics Service was Prenetics Global Ltd's largest revenue line in fiscal 2025, with $1.29M in revenue, 75.0% of the $1.72M reported across its 2 revenue lines.
Taiwan was Prenetics Global Ltd's largest region in fiscal 2023, with $27.98M in revenue, 42.9% of the $65.23M reported across its 4 regions.
Diagnostics was Prenetics Global Ltd's largest segment in fiscal 2023, with $46.76M in revenue, 71.7% of the $65.23M reported across its 2 segments.
Every figure is taken from Prenetics Global Ltd's annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by revenue line covers fiscal 2022 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.